Mass Spec: Page 3

Clinical trial planned for COVID-19 rapid breath test

By LabPulse.com staff writers

The investigational BreathTest-1000 mass spectrometer is being positioned as a noninvasive, self-administered test of breath samples for various COVID-19 strains. The developers envisage that relative to the gold standard for COVID-19 detection, polymerase chain reaction (PCR) tests, their product would be a lower-cost, more convenient option suitable for wide distribution.

October 20, 2020

Mail-in blood test created for vulnerable kids with organ transplants

By LabPulse.com staff writers

The test, which was created in response to the closures of most hospital outpatient clinics due to COVID-19, eliminates the need for immunosuppressed patients to visit hospitals for blood tests. The tests measure levels of antirejection drugs, which help minimize the risk of organ rejection and must be monitored carefully, from a dried blood spot on a piece of paper.

May 12, 2020

Biocept launches new line of molecular assay kits

By LabPulse.com staff writers

The company's Target Selector kits have been validated to identify oncogene mutations by analyzing formalin-fixed paraffin-embedded (FFPE) tissue from surgical biopsies as well as circulating tumor DNA taken from blood-based liquid biopsies, it said. The kits use Biocept's Switch Blocker technology, which enriches specimens in order to boost detection sensitivity and specificity, according to the firm. They can be used in combination with quantitative polymerase chain reaction (qPCR), Sanger sequencing, microarrays, mass spectrometry, and next-generation sequencing.

April 19, 2020

Agilent launches liquid chromatography-mass spectrometry system in U.S.

By LabPulse.com staff writers

Agilent's K6460S Clinical Edition triple quadrupole (TQ) LC-MS system is a U.S. Food and Drug Administration (FDA) class I device. It features a preset liquid chromatograph and mass spectrometer, as well as the clinical edition of the company's MassHunter software, according to the firm.

March 29, 2020

Fentanyl during moms' labor shows up in babies' urine

By Emily Hayes

The investigators evaluated urine toxicology screening results from 96 newborns, using a review of medical records, which included the type and level of anesthesia administered to mothers during labor. Of the total, 29% of neonatal samples were positive for fentanyl, reported Athena Petrides, PhD, an assistant professor of pathology at Brigham and Women's Hospital and Harvard Medical School, and colleagues.

March 24, 2020

Thermo Fisher launches Cascadion SM clinical analyzer in U.S.

By LabPulse.com staff writers

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is considered the gold standard among vitamin D testing methods, but the technique has traditionally relied on sophisticated technology requiring specialized knowledge. The Cascadion SM clinical analyzer, equipped with a built-in 25-hydroxy vitamin D assay, automatically analyzes vitamin D2 and D3 in blood samples, without the need for extensive technical expertise.

March 9, 2020

MilliporeSigma to make Elypta liquid biopsy kits

By LabPulse.com staff writers

Elypta's liquid biopsy kits analyze metabolites that are deregulated in several types of cancer, resulting in more accurate diagnoses, according to MilliporeSigma. The kits to be manufactured will use a biofluid sample to detect and analyze biological markers for cancer, enabling clinicians to diagnose patients and determine treatment options.

February 17, 2020

Thermo Fisher, NanoPin partner on infectious disease workflows

By LabPulse.com staff writers

The partnership will utilize Thermo Fisher's LC-MS technology and NanoPin's diagnostic platform to identify disease-related antigens from patient blood samples, Thermo Fisher said.

February 13, 2020

Mass spectrometry brings speed, accuracy, specificity to labs

By Joseph Constance

In the clinical setting, mass spectrometry has gained attention as a more specific alternative to immunoassays for determining the presence of sex steroids and for use in testing for illicit or abused drug use.Source: Strategic Directions International.

February 2, 2020

State of the IVD market: New cancer and infectious disease tests emerge

By Bruce Carlson

Kalorama routinely assesses market opportunities and trends using a combination of vendor interviews and secondary research, and it published its "Worldwide Market for In Vitro Diagnostic Tests" report in August. In October, Kalorama performed an updated analysis, and while general market trends have not changed from August, the firm identified new trends and made some regional assessments.

November 26, 2019

Thermo Fisher teams with Owlstone on breath tests

By LabPulse.com staff writers

Based in Cambridge, U.K., Owlstone offers its Breath Biopsy platform and developed the ReCiva breath sampler for collecting "volatile organic compounds" in breath, enabling chemical analysis and an understanding of underlying metabolic processes. The company sees the breathalyzer as being applicable across conditions, but it has focused its research on cancer, inflammatory disease, and infectious disease.

November 6, 2019

AMP lineup shows changing of the guard in molecular tech

By Bruce Carlson

The organization's annual meeting draws molecular pathologists, pharmaceutical companies, and IVD vendors. Roche, Abbott Diagnostics, Qiagen, Thermo Fisher, Quidel, and Beckman Coulter are among the vendors that will exhibit at the meeting and also run workshops and presentations. Vendor workshops on molecular pathology are described below.

November 5, 2019

Previous Page

Page 3 of 4

Next Page